Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Raveen Syan, MD, FPMRSUrothelial Carcinoma | January 21, 2025
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
View More
Raveen Syan, MD, FPMRSUrothelial Carcinoma | January 21, 2025
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Yair Lotan, MDUrothelial Carcinoma Diagnostics | January 15, 2025
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | January 13, 2025
Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors.
Emily MenendezAdvanced Urothelial Carcinoma | January 10, 2025
The indication for SG as a treatment for patients with pretreated aUC will be officially withdrawn by Gilead.
Daniel M. Geynisman, MDMuscle Invasive Urothelial Carcinoma | January 10, 2025
Dr. Geynisman reviews the RETAIN 1 trial evaluating whether certain patients with MIBC can safely avoid invasive procedures.
Mark D. Tyson, MDNon-Muscle Invasive Urothelial Carcinoma | January 9, 2025
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Yair Lotan, MDUrothelial Carcinoma Diagnostics | January 8, 2025
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Emily MenendezUpper Tract Urothelial Carcinoma | January 7, 2025
Patients who achieved a complete response after six doses of UGN-101 were followed up for 12 months after initial CR.
Mark D. Tyson, MDNon-Muscle Invasive Urothelial Carcinoma | January 7, 2025
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
Neal Shore, MD, FACSNon-Muscle Invasive Urothelial Carcinoma | January 6, 2025
Dr. Neal Shore discusses how the investigational treatment TARA-002 can aid patients during the ongoing BCG shortage.
Neal Shore, MD, FACSNon-Muscle Invasive Urothelial Carcinoma | January 6, 2025
Dr. Neal Shore reviews the history of nadofaragene firadenovec in high-risk disease, and the anticipated outcomes of ABLE-32.
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | January 3, 2025
Drs. Nizam and Packiam review the findings from a study on AI-powered biomarkers to aid NMIBC diagnosis and treatment.
Zachary BessetteRenal Cell Carcinoma | January 2, 2025
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | December 18, 2024
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | December 17, 2024
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Advertisement
Advertisement
Advertisement